Cara L Slagle, Kim T Vuong, Kelli A Krallman, Lauren Casey, Katja M Gist, Jennifer G Jetton, Catherine Joseph, Kera Luckritz, Susan D Martin, Jolyn Morgan, Kyle A Merrill, Katie Plomaritas, David Ramirez, Cheryl L Tran, H Stella Shin, Amanda N Snyder, Brynna Van Wyk, Larissa Yalon, Stuart L Goldstein, Shina Menon
{"title":"Carpediem™婴儿肾脏替代疗法：来自icon学习网络的多中心观察队列研究","authors":"Cara L Slagle, Kim T Vuong, Kelli A Krallman, Lauren Casey, Katja M Gist, Jennifer G Jetton, Catherine Joseph, Kera Luckritz, Susan D Martin, Jolyn Morgan, Kyle A Merrill, Katie Plomaritas, David Ramirez, Cheryl L Tran, H Stella Shin, Amanda N Snyder, Brynna Van Wyk, Larissa Yalon, Stuart L Goldstein, Shina Menon","doi":"10.1016/j.jpeds.2025.114838","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate indications and outcomes of Carpediem™ as the first infant-specific continuous renal replacement therapy (CRRT) platform available for clinical use in the US.</p><p><strong>Study design: </strong>A multicenter, retrospective and prospective observational study was conducted through the \"Improving CRRT Outcomes in Neonates and Infants through Interdisciplinary Collaboration (ICONIIC)\" Learning Network. Data were collected from the first four US centers utilizing Carpediem™. A treatment course was defined as sequential CRRT procedures separated by ≤72 hours. Infant cohorts were categorized by CRRT indication: end-stage kidney disease (ESKD) (ie, CRRT as a bridge to PD) and non-ESKD (all other indications).</p><p><strong>Results: </strong>Sixty-seven infants underwent 93 treatment courses using 1,538 filters and 112 vascular access catheters. Primary indication for CRRT was ESKD in 36 (54%) and acute kidney injury in 43%. Median age at first treatment was 18 (IQR: 6, 81) days, and dry weight 2.6 (IQR: 2.4, 3.1) kg for the ESKD cohort and 32 (IQR: 9, 90) days and 3.4 (IQR: 3.2, 4.5])kg for the non-ESKD cohort. Median treatment course duration was 12 (IQR: 3,24) days for ESKD compared with 4 [IQR: 1,13] days for non-ESKD infants. Survival to hospital discharge was 67% in ESKD and 60% in non-ESKD.</p><p><strong>Conclusion: </strong>In this US cohort study, CRRT survival in infants treated with Carpediem™ exceeds 60%. More than half of the treatment indications were for ESKD as a bridge to dialysis.</p>","PeriodicalId":54774,"journal":{"name":"Journal of Pediatrics","volume":" ","pages":"114838"},"PeriodicalIF":3.5000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Infant Renal Replacement Therapy Using Carpediem™: A Multicenter Observational Cohort Study from the ICONIIC Learning Network.\",\"authors\":\"Cara L Slagle, Kim T Vuong, Kelli A Krallman, Lauren Casey, Katja M Gist, Jennifer G Jetton, Catherine Joseph, Kera Luckritz, Susan D Martin, Jolyn Morgan, Kyle A Merrill, Katie Plomaritas, David Ramirez, Cheryl L Tran, H Stella Shin, Amanda N Snyder, Brynna Van Wyk, Larissa Yalon, Stuart L Goldstein, Shina Menon\",\"doi\":\"10.1016/j.jpeds.2025.114838\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate indications and outcomes of Carpediem™ as the first infant-specific continuous renal replacement therapy (CRRT) platform available for clinical use in the US.</p><p><strong>Study design: </strong>A multicenter, retrospective and prospective observational study was conducted through the \\\"Improving CRRT Outcomes in Neonates and Infants through Interdisciplinary Collaboration (ICONIIC)\\\" Learning Network. Data were collected from the first four US centers utilizing Carpediem™. A treatment course was defined as sequential CRRT procedures separated by ≤72 hours. Infant cohorts were categorized by CRRT indication: end-stage kidney disease (ESKD) (ie, CRRT as a bridge to PD) and non-ESKD (all other indications).</p><p><strong>Results: </strong>Sixty-seven infants underwent 93 treatment courses using 1,538 filters and 112 vascular access catheters. Primary indication for CRRT was ESKD in 36 (54%) and acute kidney injury in 43%. Median age at first treatment was 18 (IQR: 6, 81) days, and dry weight 2.6 (IQR: 2.4, 3.1) kg for the ESKD cohort and 32 (IQR: 9, 90) days and 3.4 (IQR: 3.2, 4.5])kg for the non-ESKD cohort. Median treatment course duration was 12 (IQR: 3,24) days for ESKD compared with 4 [IQR: 1,13] days for non-ESKD infants. Survival to hospital discharge was 67% in ESKD and 60% in non-ESKD.</p><p><strong>Conclusion: </strong>In this US cohort study, CRRT survival in infants treated with Carpediem™ exceeds 60%. More than half of the treatment indications were for ESKD as a bridge to dialysis.</p>\",\"PeriodicalId\":54774,\"journal\":{\"name\":\"Journal of Pediatrics\",\"volume\":\" \",\"pages\":\"114838\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pediatrics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jpeds.2025.114838\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jpeds.2025.114838","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
Infant Renal Replacement Therapy Using Carpediem™: A Multicenter Observational Cohort Study from the ICONIIC Learning Network.
Objective: To evaluate indications and outcomes of Carpediem™ as the first infant-specific continuous renal replacement therapy (CRRT) platform available for clinical use in the US.
Study design: A multicenter, retrospective and prospective observational study was conducted through the "Improving CRRT Outcomes in Neonates and Infants through Interdisciplinary Collaboration (ICONIIC)" Learning Network. Data were collected from the first four US centers utilizing Carpediem™. A treatment course was defined as sequential CRRT procedures separated by ≤72 hours. Infant cohorts were categorized by CRRT indication: end-stage kidney disease (ESKD) (ie, CRRT as a bridge to PD) and non-ESKD (all other indications).
Results: Sixty-seven infants underwent 93 treatment courses using 1,538 filters and 112 vascular access catheters. Primary indication for CRRT was ESKD in 36 (54%) and acute kidney injury in 43%. Median age at first treatment was 18 (IQR: 6, 81) days, and dry weight 2.6 (IQR: 2.4, 3.1) kg for the ESKD cohort and 32 (IQR: 9, 90) days and 3.4 (IQR: 3.2, 4.5])kg for the non-ESKD cohort. Median treatment course duration was 12 (IQR: 3,24) days for ESKD compared with 4 [IQR: 1,13] days for non-ESKD infants. Survival to hospital discharge was 67% in ESKD and 60% in non-ESKD.
Conclusion: In this US cohort study, CRRT survival in infants treated with Carpediem™ exceeds 60%. More than half of the treatment indications were for ESKD as a bridge to dialysis.
期刊介绍：
The Journal of Pediatrics is an international peer-reviewed journal that advances pediatric research and serves as a practical guide for pediatricians who manage health and diagnose and treat disorders in infants, children, and adolescents. The Journal publishes original work based on standards of excellence and expert review. The Journal seeks to publish high quality original articles that are immediately applicable to practice (basic science, translational research, evidence-based medicine), brief clinical and laboratory case reports, medical progress, expert commentary, grand rounds, insightful editorials, “classic” physical examinations, and novel insights into clinical and academic pediatric medicine related to every aspect of child health. Published monthly since 1932, The Journal of Pediatrics continues to promote the latest developments in pediatric medicine, child health, policy, and advocacy.
Topics covered in The Journal of Pediatrics include, but are not limited to:
General Pediatrics
Pediatric Subspecialties
Adolescent Medicine
Allergy and Immunology
Cardiology
Critical Care Medicine
Developmental-Behavioral Medicine
Endocrinology
Gastroenterology
Hematology-Oncology
Infectious Diseases
Neonatal-Perinatal Medicine
Nephrology
Neurology
Emergency Medicine
Pulmonology
Rheumatology
Genetics
Ethics
Health Service Research
Pediatric Hospitalist Medicine.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
